Literature DB >> 11850791

Clinical utility of telomerase in cancer.

Eiso Hiyama1, Keiko Hiyama.   

Abstract

This review will focus on the clinical utilities of telomerase for human cancer diagnosis. Much attention has been focused on detection of telomerase activity and its essential components (hTR and hTERT) in cancer and noncancerous tissues. Expression of hTR and hTERT is upregulated in almost all human malignant tumors but not in benign or normal tissues with the exception of germline cells, proliferative stem cells, activated lymphocytes, and certain benign tumors. Thus, telomerase is a useful marker for cancer diagnosis and in some instance as a prognostic indicator of outcome. Telomerase detection in cells derived from breast fine needle aspirates, bronchial washes, and pancreatic juices show high sensitivity and specificity for cancer detection. In tissue samples, the level of telomerase activity is a useful prognostic indicator in certain adult cancers such as gastric and colon cancers and in neuroblastomas. Immunohistochemical detection of hTERT will facilitate exact diagnosis of the telomerase positive cells and expand the application of telomerase in cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850791     DOI: 10.1038/sj.onc.1205070

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  3-O-methylfunicone, from Penicillium pinophilum, is a selective inhibitor of breast cancer stem cells.

Authors:  E Buommino; V Tirino; A De Filippis; F Silvestri; R Nicoletti; M L Ciavatta; G Pirozzi; M A Tufano
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

2.  Effects of phosphorothioate anti-sense oligodeoxynucleotides on colorectal cancer cell growth and telomerase activity.

Authors:  Xi-Shan Wang; Kuan Wang; Xue Li; Song-Bin Fu
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

3.  Genes and pathways downstream of telomerase in melanoma metastasis.

Authors:  Sepideh Bagheri; Mehdi Nosrati; Shang Li; Sylvia Fong; Sima Torabian; Javier Rangel; Dan H Moore; Scot Federman; Rebecca R Laposa; Frederick L Baehner; Richard W Sagebiel; James E Cleaver; Christopher Haqq; Robert J Debs; Elizabeth H Blackburn; Mohammed Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-17       Impact factor: 11.205

4.  Possibility of selection of chondrogenic progenitor cells by telomere length in FGF-2-expanded mesenchymal stromal cells.

Authors:  S Yanada; M Ochi; K Kojima; P Sharman; Y Yasunaga; E Hiyama
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

5.  Hypomethylating drugs efficiently decrease cytosine methylation in telomeric DNA and activate telomerase without affecting telomere lengths in tobacco cells.

Authors:  Eva Majerová; Miloslava Fojtová; Iva Mozgová; Miroslava Bittová; Jiří Fajkus
Journal:  Plant Mol Biol       Date:  2011-08-25       Impact factor: 4.076

6.  Human telomerase catalytic subunit (hTERT) suppresses p53-mediated anti-apoptotic response via induction of basic fibroblast growth factor.

Authors:  Xun Jin; Samuel Beck; Young-Woo Sohn; Jun-Kyum Kim; Sung-Hak Kim; Jinlong Yin; Xumin Pian; Sung-Chan Kim; Yun-Jaie Choi; Hyunggee Kim
Journal:  Exp Mol Med       Date:  2010-08-31       Impact factor: 8.718

7.  Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene.

Authors:  Hisashi Hisatomi; Kazuma Ohyashiki; Junko H Ohyashiki; Kumi Nagao; Taichi Kanamaru; Hiroyuki Hirata; Nozomu Hibi; Yutaka Tsukada
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

8.  Genomic instability demonstrates similarity between DCIS and invasive carcinomas.

Authors:  Christopher M Heaphy; Marco Bisoffi; Nancy E Joste; Kathy B Baumgartner; Richard N Baumgartner; Jeffrey K Griffith
Journal:  Breast Cancer Res Treat       Date:  2008-09-11       Impact factor: 4.872

9.  Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf.

Authors:  Basem S Goueli; Ralf Janknecht
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

10.  Expression of VEGF, HGF, IL-6, IL-8, MMP-9, Telomerase in Peripheral Blood of Patients with Head and Neck Squamous Cell Carcinoma.

Authors:  Dae-Young Hong; Byung-Joo Lee; Jin-Choon Lee; Jin-Sik Choi; Soo-Geun Wang; Jung-Hoon Ro
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-12-31       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.